Title
Category
Credits
Event date
Cost
The Hidden Side of Multiple Sclerosis: Harnessing Key Pathologies to Improve Outcomes Across the Multiple Sclerosis Spectrum
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Attendance
$0.00
Program DescriptionThe understanding of MS pathophysiology has rapidly advanced in recent years, prompting reevaluation of concepts that were once considered understood.
Lost in Transition: Pearls From An Interactive Workshop to Improve the Journey to Adulthood in Spinal Muscular Atrophy
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionHistorically, patients with the most severe forms of spinal muscular atrophy (SMA) were largely unable to survive into adulthood, and those that did often were treated with a palliative approach. However, with the arrival of therapies that can dramatically shift the path of the disease, more and more patients are entering life-long adult care. Unfortunately, as this transition is a new consideration, many clinicians are still learning how to coordinate and manage it appropriately. 
The Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
$0.00
Program DescriptionThe advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continues to shift away from traditional chemoimmunotherapy approaches. However, many patients eventually develop treatment resistance, driving disease progression and further limiting therapeutic options.
Alzheimer’s Disease Diagnosis Time Outs: A Deep Dive into Challenging Clinical Scenarios for Early Alzheimer's Diagnosis and Treatment
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe management of AD is at the beginning of a seismic paradigm shift. Historically, clinical strategy has been tailored to a therapeutic armamentarium that was nonspecific and directed solely at symptom management. This mindset coincides with a variety of outdated and potentially harmful assumptions such as the idea that early diagnosis provides limited clinical value. Now that anti-Aβ antibodies are making their way into the clinic, the entire spectrum of AD care, from diagnosis through therapy, must be re-engineered.
The Age of Disease Modification in Alzheimer’s Disease: A Grand Rounds Series on the Practical Implementation of Amyloid Targeting Therapies into Clinical Practice
  • 1.00 AMA PRA Category 1 Credit™
06/19/2025
$0.00
Program DescriptionFor the first time in the history of AD management, a class of therapy designed to alter the disease course for patients is finally a reality in the form of anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). And while this development represents a monumental shift in the treatment of this progressive disease, it unlocks a whole host of new challenges for clinicians in the form of significant adjustment of practice norms.